Share on StockTwits

DexCom (NASDAQ:DXCM) CEO Terrance H. Gregg sold 35,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $37.23, for a total value of $1,303,050.00. Following the sale, the chief executive officer now directly owns 395,626 shares of the company’s stock, valued at approximately $14,729,156. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $33.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $38.00.

Shares of DexCom (NASDAQ:DXCM) traded up 1.72% during mid-day trading on Wednesday, hitting $39.89. 795,479 shares of the company’s stock traded hands. DexCom has a 1-year low of $19.93 and a 1-year high of $49.83. The stock has a 50-day moving average of $33.76 and a 200-day moving average of $37.61. The company’s market cap is $2.988 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The company’s revenue for the quarter was up 59.1% on a year-over-year basis. Analysts expect that DexCom will post $-0.33 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.